Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?
Publication
, Conference
Fuh, KC; Secord, AA; Bevis, KS; Huh, WK; Blansit, K; Rosenfeld, E; Hu, L; Previs, RA; Gardner, AB; Kapp, DS; Chan, JK
Published in: Gynecologic Oncology
April 2015
Duke Scholars
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
April 2015
Volume
137
Start / End Page
56 / 56
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Fuh, K. C., Secord, A. A., Bevis, K. S., Huh, W. K., Blansit, K., Rosenfeld, E., … Chan, J. K. (2015). Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? In Gynecologic Oncology (Vol. 137, pp. 56–56). Elsevier BV. https://doi.org/10.1016/j.ygyno.2015.01.130
Fuh, K. C., A. A. Secord, K. S. Bevis, W. K. Huh, K. Blansit, E. Rosenfeld, L. Hu, et al. “Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?” In Gynecologic Oncology, 137:56–56. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.130.
Fuh KC, Secord AA, Bevis KS, Huh WK, Blansit K, Rosenfeld E, et al. Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? In: Gynecologic Oncology. Elsevier BV; 2015. p. 56–56.
Fuh, K. C., et al. “Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?” Gynecologic Oncology, vol. 137, Elsevier BV, 2015, pp. 56–56. Crossref, doi:10.1016/j.ygyno.2015.01.130.
Fuh KC, Secord AA, Bevis KS, Huh WK, Blansit K, Rosenfeld E, Hu L, Previs RA, Gardner AB, Kapp DS, Chan JK. Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? Gynecologic Oncology. Elsevier BV; 2015. p. 56–56.
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
April 2015
Volume
137
Start / End Page
56 / 56
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis